Evidence map›Paper›PMID 30755704›Full record

ArticleScientific reports2019

Development of Orthogonal Linear Separation Analysis (OLSA) to Decompose Drug Effects into Basic Components.

Tadahaya Mizuno, Setsuo Kinoshita, Takuya Ito, Shotaro Maedera, Hiroyuki Kusuhara

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Tadahaya MizunoGraduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan. tadahaya@mol.f.u-tokyo.ac.jp.ORCID 0000-0002-1638-602X
Setsuo KinoshitaGraduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Takuya ItoGraduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Shotaro MaederaGraduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Hiroyuki KusuharaGraduate School of Pharmaceutical Sciences, the University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan. kusuhara@mol.f.u-tokyo.ac.jp.
The University of Tokyo · JPProMedica Charles and Virginia Hickman Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drugs have multiple, not single, effects. Decomposition of drug effects into basic components helps us to understand the pharmacological properties of a drug and contributes to drug discovery. We have extended factor analysis and developed a novel profile data analysis method: orthogonal linear separation analysis (OLSA). OLSA contracted 11,911 genes to 118 factors from transcriptome data of MCF7 cells treated with 318 compounds in a Connectivity Map. Ontology of the main genes constituting the factors detected significant enrichment of the ontology in 65 of 118 factors and similar results were obtained in two other data sets. In further analysis of the Connectivity Map data set, one factor discriminated two Hsp90 inhibitors, geldanamycin and radicicol, while clustering analysis could not. Doxorubicin and other topoisomerase inhibitors were estimated to inhibit Na

Indexed as

Antineoplastic AgentsApoptosisAutophagyDoxorubicinHep G2 CellsHumansLipopolysaccharidesMacrophagesMCF-7 CellsMechanistic Target of Rapamycin Complex 1Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTopoisomerase InhibitorsAntineoplastic AgentsDoxorubicinLipopolysaccharidesMechanistic Target of Rapamycin Complex 1Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTopoisomerase Inhibitors

Identifiers

PMID30755704
PMCPMC6372619
OpenAlexW2936223015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.